Compare Taskus Inc (TASK) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Taskus Inc vs Tango Therapeutics Inc. — how do they compare? Taskus Inc trades at $8.1 (market cap $750.00M), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 5× Taskus Inc's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Taskus Inc for 35 Days and Tango Therapeutics Inc. for 0 Days on average.
| TASK | TNGX | |
|---|---|---|
Market Cap | $750.00M | $3.75B |
Volume | 195,383 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $14.30 | $32.90 |
52-Week Low | $4.57 | $7.50 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | $1.12B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TaskUs (TASK) trades at $8.14, up 1.88% with bullish technical signals from moving averages. The company shows strong fundamentals with revenue growth to $1.18B in 2025 and net income margin expanding to 8.75%. Valuation metrics appear attractive with P/E of 7.05 and P/S of 0.62. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.28 expected, driven by AI services growth offsetting declines in other segments.
The outlook remains positive with analyst consensus price target of $9.33 representing 15% upside potential. Key opportunities include AI services expansion growing 26% annually, while risks involve margin compression from higher labor costs and client concentration. Institutional ownership increased with Dimensional Fund Advisors raising stake by 12.8% in Q1 2026.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
